Journal of cancer research and therapeutics最新文献

{"title":"Survival prediction using CT-based radiomic features in patients of pancreatic cancer treated with chemotherapy followed by SBRT.","authors":"Divya Khosla, Gaganpreet Singh, Vandana Thakur, Rakesh Kapoor, Rajesh Gupta, Divyesh Kumar, Renu Madan, Shikha Goyal, Arun S Oinam, Surinder S Rana","doi":"10.4103/jcrt.jcrt_1595_24","DOIUrl":"10.4103/jcrt.jcrt_1595_24","url":null,"abstract":"<p><strong>Purpose: </strong>Owing to the heterogeneous nature of pancreatic cancer, clinical prediction models are not sufficient for prognostication. Radiomics is quantitative noninvasive assessment performed from imaging which by means of mathematical models can decode tumor phenotype and further predict disease and treatment outcomes. This pilot study aims to investigate the association of CT-based radiomic features with overall survival (OS) in pancreatic cancer patients treated with stereotactic body radiation therapy (SBRT).</p><p><strong>Materials and methods: </strong>This study was conducted in patients of borderline resectable and locally advanced pancreatic cancer at our institute from January 2021 to December 2022. Ten patients underwent neoadjuvant chemotherapy, followed by SBRT with doses ranging from 33 Gy to 42 Gy administered in 5-6 fractions. Subsequent treatment included additional chemotherapy and evaluation for potential surgery. Radiomic features were extracted from planning CT images, and statistical analysis was performed using R software.</p><p><strong>Results: </strong>Out of 10 patients receiving neoadjuvant chemotherapy followed by SBRT, three underwent surgery. The duration of median follow-up was 15 months, and the median OS was 25 months. A total of 851 radiomic features including 107 original images features and 93 × 8 wavelet-based features were extracted. Using Lasso Cox regression, four wavelet-based features were found to influence the overall survival.</p><p><strong>Conclusions: </strong>The present study demonstrates that CT-based radiomic features can be a promising tool in predicting survival and in addition to clinical parameters can provide detailed prognostic information that can facilitate personalized patient care. However, clinical implications of this radiomic analysis need a larger number of patients to validate the results.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"664-669"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision prediction of cervical cancer outcomes: A machine learning approach to recurrence and survival analysis.","authors":"Surendra Kumar Saini, Daya Nand Sharma, Sapna Chauhan, Shelly Srivastava, N Gopishankar, V Subramani","doi":"10.4103/jcrt.jcrt_2524_24","DOIUrl":"10.4103/jcrt.jcrt_2524_24","url":null,"abstract":"<p><strong>Abstract: </strong>Cervical cancer remains a significant global health challenge, with high rates of recurrence and mortality, particularly in low-resource regions. Effective prediction of recurrence and survival is crucial for optimizing treatment and improving patient outcomes. Recently, artificial intelligence (AI) has emerged as a transformative tool in oncology, providing advanced methodologies for analyzing large-scale medical data and offering predictive insights into patient outcomes. This review comprehensively explores the role of AI in predicting cervical cancer recurrence and survival, focusing on techniques such as machine learning, deep learning, and natural language processing. The integration of AI with medical imaging, genomics, and clinical data is discussed, along with the associated challenges and limitations. Future directions and the potential impact of AI on personalized medicine in cervical cancer care are also examined.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"538-546"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of clinicopathological factors and treatment outcomes on gastric cancer survival: A tertiary care hospital-based study in Eastern India.","authors":"Sushmita Ghosh, Raya Banerjee, Jayanta Chakrabarti, Neyaz Alam, Partha Nath, Kalyan K Mukherjee, Vilas D Nasare","doi":"10.4103/jcrt.jcrt_655_24","DOIUrl":"10.4103/jcrt.jcrt_655_24","url":null,"abstract":"<p><strong>Objective: </strong>The late diagnosis of GC poses a significant health burden worldwide, particularly in Asia. Despite the declining incidence, the heterogeneous diversity of India exhibits pronounced regional disparity in survival rates among the patients. The study observed the clinicopathological factors and treatment outcomes influencing the survival of gastric cancer (GC) patients.</p><p><strong>Methods: </strong>A total of 78 newly diagnosed GC patients were enrolled (from 2019 to 2023). Overall survival (OS) and hazard risk (HR) for sociodemographic, clinicopathological factors, and treatment outcomes of the patients were assessed by univariate Kaplan-Meier and multivariate Cox-Regression analysis.</p><p><strong>Results: </strong>The frequency of GC was highly prevalent among males (69.2%), with a median age of 52 ± 11.35 years. The majority of them are associated with mixed diet (88.5%), grade-III tumors (57.7%) located in the antrum (60.3%) at ≥5 cm (56.4%) classified as pTNM stage-III (64.1%) exhibiting lymphovascular invasion (75.6%). Clinical features, including initial symptoms, treatment response, and pTNM-stage presented increased hazard risks in the patients (HR >1) but presented no significant difference. Nearly 63% of the patients operated upfront and 37% received neoadjuvant FLOT chemotherapy. The mean overall survival of the patients was 19.7 months [95% CI: 15.9-23.5]. The hazard of death was significantly allied with older age (P < 0.001), and neoadjuvant-FLOT-chemotherapy (P < 0.001); however, a higher number of cycles of adjuvant-CAPOX-chemotherapy associated with improved overall survival (P < 0.001) and relatively lower HR.</p><p><strong>Conclusion: </strong>The clinicopathological attributes and treatment outcomes like older age, weight loss, tumor size, type of gastrectomy, FLOT regimen, number of cycles, and postoperative undernourishment demonstrated higher HR and compromised survival in GC patients of Eastern India.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"624-633"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pemphigus vulgaris following radiotherapy in head and neck cancer: Clinicopathological perspective of a rare cutaneous manifestation after radiotherapy treatment.","authors":"Saikat Das, Arnav Tiwari, Dinesh Asati, Vaishali A Walke, Manish Gupta, Vipin Kharade, Rajesh Pasricha","doi":"10.4103/jcrt.jcrt_1941_24","DOIUrl":"10.4103/jcrt.jcrt_1941_24","url":null,"abstract":"<p><strong>Abstract: </strong>Pemphigus vulgaris triggered by the radiotherapy is rare and very few cases have been reported in the literature. Lesions within the radiotherapy field can be difficult to differentiate from post radiation dermatitis. Though exact pathogenesis is not understood, radiotherapy induced immunomodulation leading to bullous skin lesions, is thought to be critical. Here we present the clinicopathological perspective of pemphigus vulgaris involving the skin within and outside the radiotherapy portal, presented 2 weeks after the completion of radiotherapy. The condition requires multidisciplinary management and close coordination between oncologist, dermatologist, and dermatopathologist. Diagnosis is established based on the clinical presentation, histopathology, and direct immunofluorescence examination. Early institution of immunosuppressive therapy can improve the skin lesions and reduce the morbidity significantly.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"767-770"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous cell carcinoma of vulva during pregnancy- A rare case report with review of literature.","authors":"Shikha Singla, Lajya D Goyal","doi":"10.4103/jcrt.jcrt_1421_24","DOIUrl":"10.4103/jcrt.jcrt_1421_24","url":null,"abstract":"<p><strong>Abstract: </strong>Vulval carcinoma accounts for just 4% of all gynecological malignancies. It rarely occurs in women under the age of 40 years and diagnosis during pregnancy is extremely rare. This is a case of vulval carcinoma in a 31-year-old multiparous woman diagnosed in the third trimester of pregnancy and had successful pregnancy outcome. There are no clear recommendations on management of vulvar cancer during pregnancy. However surgical resection and lymphadenectomy during pregnancy has comparable outcomes to that observed in non-pregnant women.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"771-774"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen receptor expression in triple negative breast cancer: A report from a tertiary care center.","authors":"Atika Dogra, Vidya Krishna, Dinesh Chandra Doval, Anurag Mehta","doi":"10.4103/jcrt.jcrt_461_24","DOIUrl":"10.4103/jcrt.jcrt_461_24","url":null,"abstract":"<p><strong>Context: </strong>The role of androgen receptor (AR) as a prognostic marker in triple negative breast cancer (TNBC) has been ambiguous since existing reports illustrate conflicting results.</p><p><strong>Aims: </strong>To compare clinicopathological features and survival between AR-positive TNBC and QNBC.</p><p><strong>Methods and material: </strong>A total of 281 subjects were included and tissue microarrays (TMA) were constructed using tumor tissue cores from their formalin-fixed paraffin-embedded blocks. The testing of AR expression was done using immunohistochemistry on TMA slides. Tumors with at least 1% nuclear staining were considered to be positive for AR expression. Comprehensive data were gathered from electronic medical records and analyzed using statistical tests.</p><p><strong>Results: </strong>The expression of AR was positive in 52 cases. The TNBC subgroup with a positive family history of cancer had a significantly higher frequency (P = 0.011) of second primary occurrence. AR expression was significantly associated with higher age at diagnosis (P = 0.006), smaller tumor size (P = 0.033), lower tumor grade (P < 0.001), non-basal-like phenotype (P < 0.001), and distant recurrence (P = 0.024). At a median follow-up period of 88 (range 0-137) months, a 10-year disease-free rate was higher in quadruple negative breast cancer (QNBC) (78% vs. 73%) compared to AR-positive TNBC. Likewise, the 10-year overall survival rate in QNBC was superior (75% vs. 72%) to AR-positive TNBC.</p><p><strong>Conclusions: </strong>AR is expressed in one-fifth of all TNBC. AR expression is associated with smaller tumor size, lower tumor grade, higher age, and distant recurrence. AR-positive TNBC exhibits shorter disease-free survival and overall survival than QNBC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"551-557"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of an adult with rhabdomyosarcoma of lung with ovarian metastases or the other way around: Do's and don'ts with review of literature.","authors":"Tushar Jassal, Vipin Kharade, Saikat Das, Manish Gupta","doi":"10.4103/jcrt.jcrt_2517_24","DOIUrl":"10.4103/jcrt.jcrt_2517_24","url":null,"abstract":"<p><strong>Abstract: </strong>Primary pulmonary rhabdomyosarcoma (RMS) is extremely rare (0.07%) in persons aged >45 years and is frequently misdiagnosed as small-cell lung cancer. Little information is available regarding the management of patients, with available literature only limited to a few case reports. We report a rare case of RMS of the lung with multiple metastases with an extensive literature review on the subject. A 52-year-old woman presented with shortness of breath, orthopnea, and chest pain for one and a half months. She also developed abdominal distension in the last month. Imaging showed a large, ill-defined solid cystic mass arising from the retroperitoneum abutting the urinary bladder with multiple adjacent small nodular deposits in serosa and peritoneum with gross ascites along with two large mass lesions in the lower lobe of the left lung and bilateral lung parenchymal metastatic deposits. The biopsy of the adnexal and lung lesions was performed along with immunohistochemistry, which was suggestive of rhabdomyosarcoma. The patient was planned for palliative chemotherapy with biweekly vincristin, adriamycin, cyclophosphamide/ifosphamide, etoposide (VAC/IE) regimen with prophylactic granulocyte-colony stimulating factor support followed by response assessment after 3-4 cycles. However, dose-compressed VAC/IE is highly myelosuppressive and lead to febrile neutropenia in our patient and thus culminated in her death. Hence, the Indian patients should be challenged with dose-compressed VAC/IE with extreme caution. Three-weekly IE/VAC regimen is an alternative.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"762-766"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective comparative study on conformal pelvic radiation with 6 MV vs. mixed energy beam for carcinoma cervix.","authors":"Rajdeep Bose, Sumitava De, Bidyut Biswas, Linkon Biswas, Sandip Ghosh","doi":"10.4103/jcrt.jcrt_678_25","DOIUrl":"10.4103/jcrt.jcrt_678_25","url":null,"abstract":"<p><strong>Background: </strong>Both low and high energy beams have their own pros and cons. But, there are very limited data available in the literature comparing monoenergetic and mixed energy beam for radiotherapy of carcinoma cervix. This study was aimed at comparing monoenergetic (6 MV) versus mixed energy beam (6 MV and 10 MV) used for treatment of carcinoma cervix in terms of dosimetric parameters and acute toxicity profile.</p><p><strong>Materials and methods: </strong>It was a single-institutional, prospective, comparative study among 60 patients with non-metastatic carcinoma cervix who received radical Radiotherapy between March 2021 and September 2022. Two radiotherapy planning were performed for each patient, one with mixed energy beam and another with 6MV energy, and treated with one of the treatment plans in a 1:1 fashion using two different energies. We compared the two plans in terms of dosimetric parameters and clinically by the acute toxicity profile.</p><p><strong>Results: </strong>The mean V95 of planning target volume (PTV) was numerically higher in the mixed beam arm (99.83 ± 0.11% vs. 99.28 ± 0.21%, P value - 0.812). Bowel sparing was slightly better in mixed beam therapy in terms of V20 of bowel (63.88% ± 8.26 vs. 64.03% ± 10.23, P value - 0.067). Mean V50 of the urinary bladder was also almost the same in both mixed and monoenergetic beam arms. Skin toxicity was significantly less in mixed beam treatment (P value < 0.05).</p><p><strong>Conclusion: </strong>For pelvic irradiation, mixed energy beam has better planning target volume coverage, better sparing of organ at risks (OARs), and better acute toxicity profile than monoenergetic beam.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"707-711"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric implications of omitting vaginal loading in hybrid brachytherapy for carcinoma cervix without vaginal infiltration.","authors":"Devender Reddy Boja, Harjot Kaur Bajwa, N V N Madhusudhana Sresty, Krishnam Raju Alluri, Hima Bindu Pitta","doi":"10.4103/jcrt.jcrt_568_24","DOIUrl":"10.4103/jcrt.jcrt_568_24","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the dosimetric parameters in hybrid brachytherapy with and without using the vaginal component for carcinoma cervix patients that do not have disease extending to the vagina.</p><p><strong>Materials and methods: </strong>Patients without vaginal involvement who received chemoradiation and hybrid brachytherapy were prospectively included for analysis. Two plans were created for each patient. The first plan (Plan 1) was created by loading the interstitial component to 10-20% of the tandem loading and reducing the vaginal loading to 30%. The second plan (Plan 2) was created by loading the tandem and interstitial component only and eliminating the vaginal loading (ovoid's). The dose delivered with brachytherapy was 21 Gy in 3 fractions. The dosimetric parameters compared between the two plans were D90 HRCTV, D98 IRCTV, TRAK, D2cc to bladder, rectum, sigmoid, and dose to the ICRU 89 RV point.</p><p><strong>Results: </strong>Thirty patients were included for analysis. The mean HRCTV volume was 30 cc. The mean D90 HRCTV was 88.1 Gy EQD2 for Plan 1 vs 87.8 Gy EQD2 for Plan 2, respectively (P = 0.113). On statistical analysis, there was a significant difference between Rectum D2cc (72.4 Gy vs 67.3 Gy) and ICRU 89 RV point dose (71.3 Gy vs 61.2 Gy) between the two plans (P = 0.0001). The mean D2cc to bladder and sigmoid was similar between the two plans.</p><p><strong>Conclusion: </strong>In carcinoma cervix patients without vaginal involvement, omission of vaginal loading in tandem and ovoid hybrid brachytherapy reduces rectum and RV point doses while maintaining target coverage.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"606-610"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interruptions and uncertainties associated in real-time fiducial tracking treatment delivery of carcinoma prostate using cyberknife radiosurgery - A monoinstitutional radiation therapists study.","authors":"Subrata Roy, P T Afnan, Deepak U Pal, Suhas Rai, Shyam K Shrivastava, P S Sridhar, Bhavin Visariya, Rehna William","doi":"10.4103/jcrt.jcrt_410_24","DOIUrl":"10.4103/jcrt.jcrt_410_24","url":null,"abstract":"<p><strong>Objective: </strong>The fiducial-based CyberKnife (CK) radiosurgery system is used to track the intrafraction motion of tumor in real time to diminish the dose to the surrounding normal tissues. Radiation therapists (RTTs) are accountable for eradicating uncertainties and interruptions and for delivering precise treatment. The intent of this study is to quantify and emphasize the list of potential uncertainties and interruptions as well as to provide solutions to reduce the treatment execution time, which may lead to improved patient satisfaction.</p><p><strong>Material and methods: </strong>This retrospective study includes 20 (n = 20) carcinoma prostate patients treated using the CK fiducial-based tracking method. Treatment uncertainties and interruptions data in the initial ten patients (P1 to P10) have been collected using case report files (CRFs). Uncertainties and interruption data were accounted and analyzed for possible solutions. Class solutions for specific error were identified and applied for further consecutive ten patients (P11 to P20). Treatment delivery execution time and patient satisfaction levels were assessed between both groups by using statistical tools and data interpretation systems.</p><p><strong>Results: </strong>The study evidently indicates that the implemented error resolving strategies significantly reduced the treatment delivery execution time by 16% and a remarkable 18.29% increment in overall patient satisfaction level.</p><p><strong>Conclusion: </strong>This study contributes treasurable insights on error resolving strategies; by adopting these standardized error resolving strategies, RTTs can accomplish less interrupted treatment delivery of carcinoma prostate in the CK system with minimal time and error interferences to achieve higher patient satisfaction.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 3","pages":"583-592"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}